Published in Clinicoecon Outcomes Res on March 14, 2011
Profile of efraloctocog alfa and its potential in the treatment of hemophilia A. J Blood Med (2015) 0.79
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res (2015) 0.79
Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment. Biotechnol Biotechnol Equip (2014) 0.75
Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand. ScientificWorldJournal (2015) 0.75
Treatment adherence in hemophilia. Patient Prefer Adherence (2017) 0.75
Markov models in medical decision making: a practical guide. Med Decis Making (1994) 8.14
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med (2007) 6.76
An introduction to Markov modelling for economic evaluation. Pharmacoeconomics (1998) 4.27
The effect of elective total hip replacement on health-related quality of life. J Bone Joint Surg Am (1993) 2.85
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood (2003) 1.57
Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia (2008) 1.28
Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia (1999) 1.23
Practice patterns in haemophilia A therapy -- global progress towards optimal care. Haemophilia (2006) 1.14
Prophylactic therapy in haemophilia. Blood Rev (2009) 1.11
Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia (2006) 1.06
Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia (2000) 0.97
Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A. Haemophilia (2009) 0.92
Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics (2002) 0.91
Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A. Biologics (2009) 0.86
Prospective controlled studies on prophylaxis: an Italian approach. Haemophilia (2003) 0.82
Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med (2013) 2.99
Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost (2013) 2.19
Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol (2005) 1.63
Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br J Haematol (2004) 1.52
Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. Blood (2013) 1.51
The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost (2002) 1.23
How we choose factor VIII to treat hemophilia. Blood (2012) 1.17
Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. Thromb Haemost (2015) 1.06
Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. Clinicoecon Outcomes Res (2013) 1.00
Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res (2011) 0.97
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood (2013) 0.96
A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res (2011) 0.94
How I treat age-related morbidities in elderly persons with hemophilia. Blood (2009) 0.92
The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica (2008) 0.91
Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol (2010) 0.89
Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up. Haematologica (2009) 0.89
Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy. Ther Clin Risk Manag (2012) 0.89
Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. Clin Chem (2005) 0.89
Factors influencing the long-term outcome of primary total knee replacement in haemophiliacs: a review of 116 procedures at a single institution. Br J Haematol (2009) 0.88
A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol (2003) 0.88
Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters. Br J Haematol (2008) 0.88
Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica (2006) 0.85
The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study. Haematologica (2006) 0.84
Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency. Br J Haematol (2002) 0.84
Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost (2008) 0.84
Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy. Transfus Med (2011) 0.84
Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression. J Clin Virol (2007) 0.83
Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation. Clinicoecon Outcomes Res (2012) 0.83
Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy. Blood Transfus (2010) 0.82
Beyond patient benefit: clinical development in hemophilia. Hematology (2012) 0.82
High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. Haematologica (2006) 0.82
Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines. Clinicoecon Outcomes Res (2013) 0.81
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest (2015) 0.81
Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost (2013) 0.81
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. Thromb Haemost (2014) 0.80
Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thromb Haemost (2015) 0.80
A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy. Clinicoecon Outcomes Res (2009) 0.80
Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey. Haemophilia (2014) 0.79
Difficult clinical challenges in haemophilia: international experiential perspectives. Haemophilia (2012) 0.79
Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy. Clinicoecon Outcomes Res (2012) 0.78
PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res (2012) 0.78
A cost-of-illness study of spina bifida in Italy. Clinicoecon Outcomes Res (2013) 0.78
Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors. Thromb Haemost (2015) 0.77
Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype. Br J Haematol (2008) 0.77
Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica (2006) 0.77
Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients. Br J Haematol (2013) 0.77
Barriers to primary prophylaxis in haemophilic children: the issue of the venous access. Blood Transfus (2008) 0.77
Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. Thromb Haemost (2015) 0.76
Investigational drugs for coagulation disorders. Expert Opin Investig Drugs (2013) 0.76
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. Thromb Haemost (2016) 0.76
Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. Thromb Haemost (2016) 0.76
Factor VIII inhibitor and source of replacement therapy. Blood Transfus (2011) 0.76
Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels. Thromb Haemost (2016) 0.76
Syringeless power injector versus dual-syringe power injector: economic evaluation of user performance, the impact on contrast enhanced computed tomography (CECT) workflow exams, and hospital costs. Med Devices (Auckl) (2013) 0.75
Global Emerging HEmophilia Panel (GEHEP): A Multinational Collaboration for Advancing Hemophilia Research and Treatment. Transfus Med Hemother (2013) 0.75
An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat (2008) 0.75
A catastrophic case of skin gangrene. Ann Ital Med Int (2005) 0.75
Increased VEGF levels in one case of papillary tumor of the pineal region with intracranial haemorrhage at presentation: a potential surrogate indicator of tumor angiogenesis and aggressiveness? J Neurosurg Sci (2016) 0.75
Managing the pediatric patient and the adolescent/adult transition. Semin Thromb Hemost (2006) 0.75
XVI Convegno Triennale sui Problemi Clinici e Sociali dell'Emofilia e delle Malattie Emorragiche Congenite, Napoli, 9-12 Novembre 2017. Blood Transfus (2017) 0.75
Molecular genetic analysis of severe coagulation factor XI deficiency in six Italian patients. Haematologica (2004) 0.75
Rationale for individualizing haemophilia care. Blood Coagul Fibrinolysis (2015) 0.75